These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21477210)

  • 1. Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
    Tadmor T; Attias D; Polliack A
    Br J Haematol; 2011 Jun; 153(5):557-67. PubMed ID: 21477210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
    Fujimura T; Mahnke K; Enk AH
    J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.
    Younos IH; Abe F; Talmadge JE
    Leuk Lymphoma; 2015; 56(8):2251-63. PubMed ID: 25407654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cell heterogeneity and subset definition.
    Peranzoni E; Zilio S; Marigo I; Dolcetti L; Zanovello P; Mandruzzato S; Bronte V
    Curr Opin Immunol; 2010 Apr; 22(2):238-44. PubMed ID: 20171075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.
    Haile LA; Gamrekelashvili J; Manns MP; Korangy F; Greten TF
    J Immunol; 2010 Jul; 185(1):203-10. PubMed ID: 20525890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients.
    Jiang J; Guo W; Liang X
    Hum Immunol; 2014 Nov; 75(11):1128-37. PubMed ID: 25305034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid metabolism related to immune tolerance by MDSCs.
    Yang B; Wang X; Ren X
    Int Rev Immunol; 2012 Jun; 31(3):177-83. PubMed ID: 22587019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
    Solito S; Bronte V; Mandruzzato S
    J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.
    Ye XZ; Yu SC; Bian XW
    J Genet Genomics; 2010 Jul; 37(7):423-30. PubMed ID: 20659706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
    Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
    Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of myeloid-derived suppressor cells.
    Ugel S; Delpozzo F; Desantis G; Papalini F; Simonato F; Sonda N; Zilio S; Bronte V
    Curr Opin Pharmacol; 2009 Aug; 9(4):470-81. PubMed ID: 19616475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
    Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
    Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
    Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription factors in myeloid-derived suppressor cell recruitment and function.
    Sonda N; Chioda M; Zilio S; Simonato F; Bronte V
    Curr Opin Immunol; 2011 Apr; 23(2):279-85. PubMed ID: 21227670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells.
    Jinushi M; Yagita H; Yoshiyama H; Tahara H
    Trends Mol Med; 2013 Sep; 19(9):536-45. PubMed ID: 23810190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-derived suppressor cells in cancer patients: a clinical perspective.
    Montero AJ; Diaz-Montero CM; Kyriakopoulos CE; Bronte V; Mandruzzato S
    J Immunother; 2012; 35(2):107-15. PubMed ID: 22306898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-derived suppressor cells in cancer: recent progress and prospects.
    Khaled YS; Ammori BJ; Elkord E
    Immunol Cell Biol; 2013 Sep; 91(8):493-502. PubMed ID: 23797066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.
    Katoh H; Watanabe M
    Mediators Inflamm; 2015; 2015():159269. PubMed ID: 26078490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-derived suppressor cells in human cancer.
    Nagaraj S; Gabrilovich DI
    Cancer J; 2010; 16(4):348-53. PubMed ID: 20693846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.
    Pan W; Sun Q; Wang Y; Wang J; Cao S; Ren X
    Tumour Biol; 2015 May; 36(5):3159-69. PubMed ID: 25828146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.